10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 [Accessibility Statement] Skip NavigationPLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- [10x Genomics, Inc.](Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026.Recent Updates- Ended the year with $523.4 million of cash and cash equivalents and marketable securities, an ...

Group 1 - Bold Ventures Inc. has successfully closed a non-brokered private placement offering, raising gross proceeds of $200,000 through the sale of 2,500,000 working capital units at a price of $0.08 per unit [1][3] - The company paid a cash finder's fee of $11,200 and issued 140,000 compensation warrants, each allowing the holder to acquire one common share at a price of $0.12 until January 21, 2029 [2] - The proceeds from the offering will be allocated for general working capital, property maintenance, exploration, and expenses related to the offering [3] Group 2 - Bold Ventures focuses on the exploration of Precious, Battery, and Critical Metals in Canada, targeting commodities such as Copper, Nickel, Lead, Zinc, Gold, Silver, Platinum, Palladium, and Chromium [4] - The company is exploring properties in active gold and battery metals camps located in the Thunder Bay and Wawa regions of Ontario, as well as significant assets in the emerging multi-metals district known as the Ring of Fire in Northern Ontario [5]

Summary of 10X Genomics FY Conference Call Company Overview - **Company**: 10X Genomics (NasdaqGS:TXG) - **Event**: FY Conference on January 12, 2026 - **Revenue**: $599 million for FY 2025, $166 million for Q4 2025, exceeding guidance [3][38] Core Industry Insights - **Industry**: Life Sciences Tools and Diagnostics - **Market Position**: 10X Genomics is positioned as a leader in single-cell analysis and spatial biology, emphasizing the importance of understanding biology at the cellular level [4][9][12] Key Points and Arguments 1. **Financial Performance**: - Achieved $599 million in total revenue for FY 2025, with a strong Q4 performance of $166 million [3] - Generated $40 million in cash, strengthening the balance sheet to over $500 million [3] 2. **Innovation and Product Development**: - Focus on building technologies to measure complex biological interactions at scale and resolution [5][6] - Launched multiple new products, including the Flex assay, which has become the most popular assay by volume [14][39] - Emphasis on single-cell and spatial analysis technologies, which are foundational for understanding health and disease [11][17] 3. **Market Trends**: - Increased interest in single-cell analysis driven by new applications and AI projects [13] - Spatial analysis technologies (Visium and Xenium) are gaining traction, with customers expressing high satisfaction [16][49] 4. **Customer Engagement**: - Strong customer momentum observed, particularly in the uptake of new products [39] - Positive feedback from customers regarding the performance and utility of products [10][54] 5. **Challenges and Opportunities**: - The capital equipment market remains challenging, with tightening budgets impacting instrument sales [40][46] - Despite challenges, there is optimism about future growth driven by translational research and diagnostics applications [27][30] 6. **AI Integration**: - AI is seen as a transformative force in biology, with potential to drive demand for data generation and analysis [19][55] - Collaboration with Anthropic aims to leverage AI for data analysis, addressing bottlenecks in bioinformatics [56] 7. **Translational Research**: - Increasing adoption of products in translational research, particularly in oncology and autoimmune diseases [27][32] - Partnerships with leading medical institutions to generate clinical evidence and develop diagnostic applications [35][31] 8. **Future Outlook**: - Plans to establish a CLIA lab to facilitate clinical deployment of diagnostic tests [31] - Anticipation of significant growth in diagnostics applications, particularly in precision medicine [30][34] Additional Important Insights - **Publications and Impact**: Over 10,000 papers published using 10X products, indicating widespread adoption and impact in various fields of biology [11] - **Customer Support**: Strong customer support and satisfaction metrics, with high Net Promoter Scores (NPS) [10] - **Acquisition of Scale Biosciences**: Expected to enhance capabilities in scaling experiments, though financial impact is minimal at this stage [58] Conclusion 10X Genomics is well-positioned in the life sciences industry, with a strong focus on innovation, customer engagement, and the integration of AI technologies. The company is navigating challenges in the capital equipment market while capitalizing on growth opportunities in translational research and diagnostics.

Financial Performance - Preliminary full-year 2025 revenue is approximately $599 million, excluding $44 million related to patent litigation settlements[5,6] - Q4 2025 revenue is approximately $166 million[6] - The company's cash balance grew by over $100 million compared to year-end 2024[7] Product and Market Leadership - 10x Genomics has launched over 35 major products in the last 10 years[16] - The company has over 2,700 patents and applications[16] - Over 6,400 Chromium instruments have been sold cumulatively[34] - Over 1,500 spatial instruments have been sold cumulatively[38] Technological Advancements and Partnerships - Chromium consumables reactions growth of more than 20%[7] - Spatial Consumables revenue growth of 19%[7] - The company is building an AI-ready immuno-oncology data engine powered by 10x, generating high-resolution molecular data from over 20,000 samples and profiling over 500 million cells[52] Translational Research and Future Applications - The company is collaborating to build the world's largest single-cell dataset derived from a single cohort of >1,000 immunotherapy patients[61] - Spatial multiomics data from ~7,000 patients to ID new disease biology, patient subtypes, biomarkers, and drug types[60]

Core Viewpoint - Bold Ventures Inc. has successfully closed a non-brokered private placement offering, raising gross proceeds of $776,800 through the issuance of working capital units and flow-through units, aimed at supporting its exploration projects in Canada [1][3]. Offering Details - The offering consisted of 6,000,000 working capital units priced at $0.08 each, generating $480,000, and 3,297,776 flow-through units priced at $0.09 each, generating $296,800 [1]. - Each working capital unit includes one common share and one full common share purchase warrant, allowing the holder to acquire an additional common share at $0.12 until December 31, 2028 [4]. - Each flow-through unit comprises one common share and half of a common share purchase warrant, with one full warrant allowing the acquisition of an additional common share at $0.12 until December 31, 2027 [5]. Financial Aspects - The company paid finder fees totaling $36,719.99 and issued 454,333 compensation warrants to two eligible finders, with different expiration dates for the warrants [2]. - Insider subscriptions included three insiders who purchased 420,000 flow-through units for gross proceeds of $37,800, exempt from certain regulatory requirements [3]. Use of Proceeds - Proceeds from the working capital units will be allocated for general working capital, property maintenance, exploration, and offering expenses [4]. - Proceeds from the flow-through units will be directed towards exploration work qualifying for Canadian Exploration Expenses [5]. Company Focus - Bold Ventures is focused on exploring precious, battery, and critical metals in Canada, particularly in regions with active gold and battery metals camps [6][7]. - The company targets a range of commodities including Copper, Nickel, Lead, Zinc, Gold, Silver, Platinum, Palladium, and Chromium, aligning with future demand for these metals [6].

Core Insights - The company reported solid business fundamentals despite a challenging funding environment, with key positive drivers of performance continuing into Q2 [1][2] - Total revenue for Q2 was $173 million, with a notable settlement payment of $68 million from patent litigation contributing to the financial results [4][21] - The company is focused on advancing technology leadership in single-cell and spatial biology, with new product launches expected to enhance capabilities and drive growth [10][12] Financial Performance - Total revenue for Q2 was $172.9 million, representing a 13% increase year-over-year, while excluding the settlement revenue, it was $145.6 million, down 5% [21] - Consumables revenue was $122.2 million, down 1%, with spatial consumables revenue increasing by 24% to $36.4 million, driven by Xenium products [21] - Operating income for Q2 was $30.1 million compared to an operating loss of $41.7 million in the previous year, indicating a significant turnaround [24][25] Market Dynamics - The funding environment remains uncertain, particularly in the academic sector, leading to cautious customer spending and extended project timelines [2][7] - Despite these challenges, there is a strong demand for single-cell and spatial biology tools, with researchers increasingly investing in these technologies [8][9] - The company noted a temporary increase in purchasing activity in China, driven by customers accelerating orders ahead of potential tariff changes, estimating a $4 million revenue impact from this pull forward [23][51] Product Development and Innovation - The company launched several new products, including Visium HD 3 Prime and Flex v2, aimed at increasing throughput and lowering costs for researchers [10][11] - The acquisition of Scale Biosciences is expected to enhance the company's capabilities in single-cell analysis, making it more powerful and accessible [16][17][18] - The company is prioritizing the integration of new technologies to support larger-scale applications and maintain high-quality data standards [17][18] Customer Engagement and Sentiment - The company is closely monitoring customer sentiment and remains aligned with them to navigate the uncertain funding landscape [2][7] - Conversations with customers indicate that clarity on future budgets and the actual disbursement of funds are critical for unlocking spending [8][64] - The company is optimistic about the long-term potential of its products, as customer feedback remains positive regarding the quality and utility of its offerings [6][48]

Core Viewpoint - Fancamp Exploration Ltd. has announced a normal course issuer bid (NCIB) to repurchase up to 12,118,116 common shares, representing approximately 5% of its outstanding shares, as a strategy to enhance long-term shareholder value and address perceived undervaluation of its stock [1][3][2]. Summary by Sections Normal Course Issuer Bid (NCIB) - The Board of Directors has authorized the NCIB, which is subject to approval from the TSX Venture Exchange (TSX-V) [1]. - The NCIB is expected to commence around December 16, 2025, and will last for 12 months unless completed or terminated earlier [4]. - The purchases will be made on the open market at prevailing market prices, with the actual number and timing of shares purchased dependent on market conditions [2][3]. Management Commentary - Rajesh Sharma, President and CEO, stated that the NCIB reflects the belief that the current share price does not accurately represent the Corporation's value and future prospects, especially during the Spin Out process [2]. Financial Strategy - The Corporation views the repurchase of its shares as a suitable use of financial resources aimed at increasing long-term shareholder value [3]. - The NCIB is part of a broader strategy to enhance shareholder returns amid ongoing developments in the Corporation's business [3]. Additional Updates - Fancamp has entered into an amendment to an option agreement with Harfang Exploration Inc. to acquire up to an 80% interest in the Egan mineral property, pending TSX-V approval [6]. - The amendment specifies that shares issued to Harfang will be priced based on the volume-weighted average trading price over the preceding 10 trading days, with a minimum price of $0.064 per share [6]. Company Overview - Fancamp is focused on mineral exploration with interests in various high-potential projects across Canada, including copper, gold, zinc, and titanium [7]. - The Corporation holds significant interests in several mining operations and is developing advanced technologies for titanium extraction and waste recycling [8].

Core Viewpoint - Fancamp Exploration Ltd. has authorized a normal course issuer bid (NCIB) to repurchase up to 12,118,116 common shares, representing approximately 5% of its outstanding shares, as a strategy to enhance long-term shareholder value and address perceived undervaluation of its stock [1][3][4] Group 1: Normal Course Issuer Bid (NCIB) - The NCIB is subject to approval from the TSX Venture Exchange and is expected to commence around December 16, 2025, lasting for 12 months or until completed [4] - The purchases will be made on the open market at prevailing market prices, with the actual number and timing of repurchases dependent on market conditions [2][3] - The Board believes that repurchasing shares is an appropriate use of financial resources to increase shareholder value [3] Group 2: Management Commentary - Rajesh Sharma, President and CEO, stated that the NCIB reflects the belief that the current share price does not accurately represent the company's future prospects, especially during the spin-out process [2] - The management team is focused on creating value through strategic interests in high-potential mineral projects and monetization opportunities [7][8] Group 3: Recent Developments - Fancamp has entered into an amendment to an option agreement with Harfang Exploration Inc. to acquire up to an 80% interest in the Egan mineral property, contingent on TSX-V approval [6] - The amendment specifies that shares issued to Harfang will be priced based on the volume-weighted average trading price over the preceding 10 trading days, with a minimum price of $0.064 per share [6]

Core Viewpoint - Inomin Mines Inc. experienced a significant share price increase of 20% during trading, indicating heightened investor interest and activity in the stock [1][2]. Group 1: Stock Performance - The share price rose to a high of C$0.10 before closing at C$0.09, up from a previous close of C$0.08 [1]. - Trading volume surged to approximately 902,372 shares, marking an 821% increase compared to the average daily volume of 98,010 shares [1]. - The stock's 50-day simple moving average is C$0.08, while the 200-day simple moving average is C$0.05 [2]. Group 2: Company Overview - Inomin Mines Inc. is an exploration stage company focused on the identification, acquisition, exploration, and evaluation of mineral properties in Canada and Mexico [3]. - The company explores for various mineral deposits, including magnesium, nickel, gold, silver, copper, chromium, cobalt, and zinc [3]. - Inomin Mines was incorporated in 2012 and is based in Vancouver, Canada [3]. Group 3: Financial Metrics - The company has a market capitalization of C$4.41 million [2]. - Inomin Mines has a price-to-earnings (PE) ratio of -9.00, indicating it is currently operating at a loss [2]. - The stock has a beta of 4.97, suggesting high volatility compared to the market [2].

Group 1 - Inomin Mines Inc.'s stock price increased by 20% during trading, reaching a high of C$0.10 and last trading at C$0.09 [1] - The trading volume surged to 902,372 shares, an increase of 821% compared to the average session volume of 98,010 shares, with the previous close at C$0.08 [1] Group 2 - Inomin Mines has a market capitalization of C$4.41 million, a P/E ratio of -9.00, and a beta of 4.97 [2] - The company's 50-day moving average price is C$0.08, while the 200-day moving average price is C$0.05 [2] Group 3 - Inomin Mines Inc. is an exploration stage company focused on identifying, acquiring, exploring, and evaluating mineral properties in Canada and Mexico, targeting deposits of magnesium, nickel, gold, silver, copper, chromium, cobalt, and zinc [3] - The company was incorporated in 2012 and is based in Vancouver, Canada [3]